Loading...

ANNX ANNEXON INC Expansion Plans 8-K Filing

NNXN

NNX

ANNEXON INC

(ANNX)

2026 8-K

Quarterly Financial Update

Financial Results Report

Board Retirement

Corporate Presentation Update

Strategic Priorities Update

Stock Offering Details

Q3 Financial Results

Financial Results

Common Warrant Amendments

Financial Statements

Financial Results

2025 Outlook Announcement

Director Appointment

Positive Study Results

Q3 2024 Results

Q2 2024 Results

Update on ARCHER II Global ...

Positive Phase 3 Results fo...

Annual Meeting Voting Results

Underwriting Agreement

Phase 3 Trial Results

Financial Results Announcement

Financial Results

R&D Day Presentation

Filing Correction and Under...

Entry into a Material Defin...

Global Registrational Progr...

Financial Results

Financial Results

Appointment, Trial Results

Annual Meeting Voting Results

Results Announcement

Financial Results

Financial Results Announcement

Investor Conferences

Appointment of Chief Scient...

External Links:

On January 12, 2026, Annexon, Inc. announced its plan to accelerate its immunotherapy platform for treating neuroinflammatory diseases, setting multiple key milestones for 2026. This filing indicates a positive outlook for the company.

AI Assistant

ANNEXON INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.